Outcome of Patients With Acute Myeloid Leukemias or Myelodysplastic Syndromes After Relapsing From Allogeneic Stem Cell Transplantation: The GITMO AML/MDS-Relapse Registry Study

Disease relapse represents the main cause of treatment failure after allogeneic stem cell transplantation (Allo-SCT) in Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS) patients [1]. Thus, minimal residual disease (MRD) monitoring following allo-SCT is a mainstay of good clinical practice. The prognosis following relapse is dismal, and recently new treatment options, such as hypomethylating agents (HMAs) alone or in combination with venetoclax (VEN), have been used also in the setting of post-transplant disease relapse, but data from prospective trials are lacking.